Savara’s Molgramostim: Strong Buy Rating Backed by Clinical and Real-World Evidence for aPAP Treatment
In a report released today, Jonathan Wolleben from JMP Securities reiterated a Buy rating on Savara (SVRA – Research Report), with a price ...
Exelixis stock holds Market Outperform rating, $41 target
JMP Securities maintained a positive stance on Exelixis (NASDAQ:EXEL) stock, reiterating a Market Outperform rating with a ...
Orchid Island Capital signals positive net interest spread amid up-in-coupon portfolio shift
Cauley expressed optimism about the market environment, emphasizing the attractive spreads of current coupon mortgages and the positive impact of dollar-roll improvements on the mortgage sector. He ...
Yahoo Finance27d
JMP Expects a ‘Value-Creating Year’ for These 2 High-Yield Dividend Stocks
Covering some solid dividend stocks for JMP, analyst Aaron Hecht sees a reason to bet on higher value in the coming year. He notes that multiple tailwinds are coming together, and will likely lead ...
Raymond James price target raised to $172 from $160 at TD Cowen
TD Cowen raised the firm’s price target on Raymond James (RJF) to $172 from $160 and keeps a Hold rating on the shares. The firm said they came ...
Seeking Alpha9d
Dynex Capital, Inc. (DX) Q4 2024 Earnings Call Transcript
So the MBS market has discounted, for the most part, the probability of change. And if there is any sort of risk premium that's being built in, the probability assigned to it is small. One of the ...